Andrographolide Protects Against Adverse Cardiac Remodeling After Myocardial Infarction through Enhancing Nrf2...

Area of Science:

• Cardiovascular Biology
• Pharmacology
• Molecular Medicine

Background:

• Adverse cardiac remodeling post-myocardial infarction (MI) leads to high mortality.
• Current therapies struggle to fully preserve cardiac function and structure.
• Identifying novel therapeutic targets for post-MI recovery is crucial.

Purpose of the Study:

• To investigate the protective effects of Andrographolide (Andr) on cardiac remodeling after MI.
• To elucidate the underlying molecular mechanisms of Andr's cardioprotective action.

Main Methods:

• Myocardial infarction induced by LAD ligation in a mouse model.
• Administration of Andrographolide (Andr) and assessment of cardiac function and structure.
• Evaluation of fibrosis, inflammation, oxidative stress, and Nrf2/HO-1 signaling pathway activation.
• In vitro studies using H9C2 cells with hypoxia, Andr, and Nrf2 inhibition.

Main Results:

• Andrographolide (Andr) significantly attenuated cardiac fibrosis and inflammation post-MI.
• Andr reduced oxidative stress and inhibited p-P65 nuclear translocation.
• Andr activated the Nrf2/HO-1 signaling pathway, enhancing antioxidative capacity.
• In vitro, Andr's protective effects were dependent on Nrf2 activation.

Conclusions:

• Andrographolide (Andr) ameliorates adverse cardiac remodeling following myocardial infarction.
• The cardioprotective effects of Andr are mediated by the activation of the Nrf2 signaling pathway.
• Andr represents a potential therapeutic agent for mitigating post-MI cardiac damage.